# US 2014/0271727 A1 · Method of using an antidepressant for increasing immunity of a subject and treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271727 A1
- Document ID: US20140271727A1
- Status: Published application
- Kind: A1
- Application number: 13/846,753
- Filed: 2013-03-18
- Published: 2014-09-18
- Earliest claimed: 2013-03-18
- Assignees: National Yang-Ming University
- Applicants: National Yang-Ming University
- Inventors: Jeng-Jong Hwang; Chun-Kai Fang
- Web page: https://patentgrep.com/patent/US20140271727A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of increasing immunity of a subject by administering an antidepressant to the subject is disclosed in the present invention. Preferably, the antidepressant is mirtazapine. And further, another object of the present invention is related to a method of administering the abovementioned antidepressant to the subject for treating cancer. The present invention tries to find the mechanism of the tumor growth inhibition by mirtazapine, and it may be due to the alteration of the tumor microenvironment, which involves the activation of the immune response and the recovery of serotonin level.

## Claims

### Claim 1

A method of increasing immunity of a subject comprising:
administering an antidepressant to the subject, wherein the antidepressant is mirtazapine.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the subject is a patient with at least a cancer.

### Claim 3 (depends on 2)

The method according to claim 2 further inhibiting the tumor growth.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antidepressant increases the concentration of cytokine within the subject.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the cytokine at least comprises IL-12.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antidepressant increases the concentration of serotonin within the subject.

### Claim 7

A method of administering an antidepressant to a subject for treating cancer, wherein the antidepressant is mirtazapine.

### Claim 8 (depends on 7)

The method according to claim 7 being achieved by increasing immunity of the subject.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the subject is a patient with at least a cancer.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the cancer can be choose from a group consisting of squamous cell carcinoma, lobular carcinoma in situ, liver cancer, nasopharyngeal carcinoma, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancers, malignant melanom, cervical cancer, ovarian cancer, colon cancer, anal cancer, stomach cancer, breast cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, esophageal cancer, thyroid cancer, adrenal cancer, cancers of mesothelial and soft tissue, urethra cancer, cancer of penis, prostate cancer, acute leukaemia, chronic leukaemia, lymphomas, bladder cancer, ureteral cancer, renal cell carcinoma, urothelial carcinoma, cancer of central nervous system, primary central nervous system lymphoma, glioma, pituitary tumor, Kaposi's sarcoma, squameous cell cancer and their metastasis.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the antidepressant increases the concentration of cytokine within the subject.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the cytokine at least comprises IL-12.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the antidepressant increases the concentration of IFN-γ within the subject by the induction of IL-12.

### Claim 14 (depends on 7)

The method according to claim 7, wherein the antidepressant increases the amount of CD4+ and CD8+ T cells.

### Claim 15 (depends on 7)

The method according to claim 7, wherein the antidepressant inhibits the production of TNF-α within the tumor.

### Claim 16 (depends on 7)

The method according to claim 7, wherein a frequency of administering the antidepressant to the subject is once a day, and a dose of the antidepressant is 7.5-60 mg/day.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the dose of the antidepressant is 30 mg/day.
